- RecruitingPHASE2
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
This study is testing a new under-the-skin injection, REGN7999, for adults with non-transfusion dependent beta-thalassemia and too much iron. It aims to check if the drug is safe, works well, and lowers iron levels, using MRI scans to measure iron.
For: Non-Transfusion Dependent Beta-Thalassemia (NTDT)United States · Georgia · Greece - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ASCENDING DOSES OF REGN7999, A TMPRSS6 ANTAGONIST, IN HEALTHY ADULT SUBJECTS
This early-stage study is testing a new medicine called REGN7999 in healthy people. We want to see if it's safe, how the body handles it, and if it could help with conditions where people have too much iron.
For: Healthy - R7999 being developed for the treatment of diseases associated with iron overload.Belgium - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Subcutaneously Administered REGN7999 (An Inhibitor of TMPRSS6) in Participants with Iron Overload Due to Non-Transfusion Dependent β-Thalassemia.
This study is testing a new medicine (REGN7999) for adults with a gentle type of beta-thalassemia (NTDT) and too much iron in their body. It aims to see if the medicine can reduce iron levels and improve health, compared to a placebo, with minimal side effects.
For: Non-transfusion dependent beta-thalassemia (NTDT) · Beta-thalassemia Resultant Iron overload (IOL)Greece · Italy